Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Blood(2021)

引用 4|浏览8
暂无评分
摘要
Introduction
更多
查看译文
关键词
sickle cell disease,selective pde9 inhibitor,increases hbf,long-term,open-label
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要